Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Chronic hepatitis B treatment DC vaccine

A chronic hepatitis B, therapeutic technology, applied in the field of biomedicine, can solve problems such as inability to produce therapeutic effects, and achieve the effects of improving efficiency, high infection rate, and enhancing immune effects

Active Publication Date: 2017-11-10
SHANDONG XINRUI BIOTECH CO LTD
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is a strong immune tolerance state in the S region, which can not be used as a vaccine directly to produce therapeutic effects in HBV-tolerant mice

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chronic hepatitis B treatment DC vaccine
  • Chronic hepatitis B treatment DC vaccine
  • Chronic hepatitis B treatment DC vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0023] The specific implementation is as follows:

[0024] 1. Insert the gene fragment GM-CSFR SP-M-HBsAg into the lentiviral expression vector pLent-C-GFP.

[0025] (1) GM-CSFR SP nucleic acid artificial sequence (SEQ ID NO.1)

[0026] (2) M-HBsAg nucleic acid artificial sequence (SEQ ID NO.2)

[0027] The two ends of the nucleic acid artificial sequence of GM-CSFR SP-M-HBsAg were respectively added with NotI and AsiSI site enzyme cutting sites (SEQ ID NO.4), and entrusted Sangon Bioengineering Co., Ltd. to synthesize two complete expression cassettes. After cleavage, insert the NotI-AsiSI site of the lentiviral pLent-C-GFP vector (Invitrogen), transform into E.coli (DH5α), and after the correct identification by nucleic acid sequencing, use the plasmid purification kit from Qiagen to extract and purify the plasmid. Obtain high-quality plasmids for recombinant expression vectors.

[0028] 2. Recombinant lentivirus packaging, titer detection

[0029] Inoculate the lentivir...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Titeraaaaaaaaaa
Login to View More

Abstract

The invention discloses a chronic hepatitis B treatment DC vaccine, which comprises genetically modified dendritic cells, wherein the genetically modified dendritic cells contain a fusion gene fragment for the granulocyte-macrophage cluster factor receptor signal peptide guided encoding of the preS2 region and the S region of M-HBsAg. According to the present invention, when the body is immunized with the chronic hepatitis B treatment DC vaccine, the specific antibodies against the pres2 antigen can be produced, can well neutralize HBV viruses so as to protect the host from the HBV infection, can induce the serological transformation from HBsAg to HBsAb, can reduce the hepatitis B virus infection in the liver, and can enhance the immunization effect.

Description

technical field [0001] The invention relates to the technical field of biomedicine, more specifically, a chronic hepatitis B therapeutic DC vaccine. Background technique [0002] Hepatitis B virus (HBV), the most prevalent hepatotropic virus in the world, can cause acute, chronic and severe hepatitis after infection, and is closely related to the pathogenesis of liver cirrhosis and liver cancer. In my country, there are about 93 million HBV carriers, including 25 million chronic hepatitis B patients, which is one of the three most serious infectious diseases in my country. Currently, the main therapeutic drugs for patients with chronic hepatitis B clinically include nucleoside (acid) analogues, interferon and immunomodulators. None of these drugs can completely eliminate hepatitis B virus, and the recurrence rate is high. Therefore, it is extremely urgent to develop effective therapeutic strategies. [0003] How to induce a strong specific cellular immune response and brea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/29A61P31/20A61P1/16C12N15/86C12N15/62C12N5/10C12N5/0784
CPCA61K39/12A61K2039/5154C07K14/005C07K2319/02C12N5/0639C12N15/867C12N2510/00C12N2730/10134C12N2740/15043
Inventor 刘明录王立新冯建海姜夕锋万磊张传鹏强邦明金海锋韩庆梅
Owner SHANDONG XINRUI BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products